Anavex Life Sciences Corp (AVXL)

[sokol]

Thank you for the sensational post, Bio. I have been on the sidelines, but I recall your many valuable contributions to this board over the years. You are correct—another way of looking at this Biogen approval is that most generally, whether they be investors, doctors, patients, caregivers, families of patients, or whoever tends to believe in big pharma. Everyone, including the media that caters to the public, likely ignore young biotechs. The belief is that bigger is better. It's another version of the Too Big to Fail Theory, although big pharma has done nothing but fail when it comes to developing a meaningful Alzheimer's drug. However, the FDA now, intentionally or not, set up this plaque mania hypothesis to die once and for all. The media is shifting its attention to the controversy surrounding the approval of this drug. Once that process begins, it tends to feed on itself. Biogen is rapidly getting bad press. Anavex and other biotech startups, on the other hand, are making headway on getting attention.

Before closing, I think that the FDA's decision to approve Adu will make it easier for Anavex to gain approval. The FDA based its Biogen decision solely on a biomarker, plaque, in concluding that this biomarker is "reasonably likely to predict a clinical benefit to patients." Anavex may demonstrate multiple biomarkers and produce additional evidence of AVXL 2-73's clinical benefit to patients.